AC
IBRX icon

AXQ Capital’s ImmunityBio IBRX Stock Holding History

AXQ Capital’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
114,978
+80,728
+236% +$611K 0.11% 291
2026
Q1 		$263K Buy
34,250
+488
+1% +$3.34K 0.03% 637
2025
Q4 		$66.8K Sell
33,762
-37,538
-53% -$85K 0.02% 681
2025
Q3 		$175K Buy
71,300
+51,678
+263% +$133K 0.07% 471
2025
Q2 		$51.8K Buy
19,622
+4,948
+34% +$13.3K 0.02% 539
2025
Q1 		$44.2K Buy
+14,674
New +$44.5K 0.02% 470
2024
Q1 		– Sell
-12,400
Closed -$62.2K – 754
2023
Q4 		$62.2K Buy
+12,400
New +$38.9K 0.02% 618
2023
Q1 		– Sell
-16,407
Closed -$83.2K – 551
2022
Q4 		$83.2K Buy
+16,407
New +$90.1K 0.06% 304

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AXQ Capital's IBRX Position: Q2 2026 in Review

AXQ Capital increased its ImmunityBio (IBRX) stake by 236% in Q2 2026, buying an estimated $611K and bringing the position to 114,978 shares worth $1.01M. The position accounts for 0.11% of the portfolio, ranked #291.

AXQ Capital first reported a position in IBRX in Q4 2022 and has held it in 8 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • AXQ Capital held 114,978 shares of ImmunityBio worth $1.01M as of Q2 2026.
  • AXQ Capital bought 80,728 ImmunityBio shares in Q2 2026, an estimated $611K.
  • ImmunityBio made up 0.11% of AXQ Capital's portfolio in Q2 2026, its #291 holding.
  • AXQ Capital first reported a position in ImmunityBio in Q4 2022 and has held it in 8 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.